D
Donna M. Jacobsen
Researcher at International AIDS Society
Publications - 27
Citations - 16183
Donna M. Jacobsen is an academic researcher from International AIDS Society. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Drug resistance. The author has an hindex of 22, co-authored 25 publications receiving 15603 citations. Previous affiliations of Donna M. Jacobsen include University of Paris.
Papers
More filters
Journal ArticleDOI
Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel
Huldrych F. Günthard,Judith A. Aberg,Joseph J. Eron,Jennifer F Hoy,Amalio Telenti,Constance A. Benson,David M. Burger,Pedro Cahn,Joel E. Gallant,Marshall J. Glesby,Peter Reiss,Michael S. Saag,David L. Thomas,Donna M. Jacobsen,Paul A. Volberding +14 more
TL;DR: This report provides guidelines for when to initiate antiretroviral therapy, selection of appropriate initial regimens, patient monitoring, when to change therapy, and what regimens to use when changing.
Journal ArticleDOI
Antiretroviral Therapy for HIV Infection in 1997: Updated Recommendations of the International AIDS Society—USA Panel
Charles C. J. Carpenter,Margaret A. Fischl,Scott M. Hammer,Martin S. Hirsch,Donna M. Jacobsen,David Katzenstein,Julio S. G. Montaner,Douglas D. Richman,Michael S. Saag,Robert T. Schooley,Melanie A. Thompson,Stefano Vella,Patrick Yeni,Paul A. Volberding +13 more
TL;DR: Accumulating data from clinical and pathogenesis studies continue to support early institution of potent antiretroviral therapy in patients with HIV infection, and increased complexity in HIV management requires ongoing monitoring of new data for optimal treatment of HIV infection.
Journal ArticleDOI
Antiretroviral Therapy for HIV Infection in 1998: Updated Recommendations of the International AIDS Society–USA Panel
Charles C. J. Carpenter,Margaret A. Fischl,Scott M. Hammer,Martin S. Hirsch,Donna M. Jacobsen,David Katzenstein,Julio S. G. Montaner,Douglas D. Richman,Michael S. Saag,Robert T. Schooley,Melanie A. Thompson,Stefano Vella,Patrick Yeni,Paul A. Volberding +13 more
TL;DR: New data have provided a stronger rationale for earlier initiation of more aggressive therapy than previously recommended and reinforce the importance of careful selection of initial drug regimen for each patient for optimal long-term clinical benefit and adherence.
Journal ArticleDOI
Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel
Charles C. J. Carpenter,David A. Cooper,Margaret A. Fischl,Jose M. Gatell,Brian Gazzard,Scott M. Hammer,Martin S. Hirsch,Donna M. Jacobsen,David Katzenstein,Julio S. G. Montaner,Douglas D. Richman,Michael S. Saag,Mauro Schechter,Robert T. Schooley,Melanie A. Thompson,Stefano Vella,Patrick Yeni,Paul A. Volberding +17 more
TL;DR: The availability of new antiretroviral drugs has expanded treatment choices and the importance of adherence, emerging long-term complications of therapy, recognition and management of antireTroviral failure, and new monitoring tools are addressed.
Journal ArticleDOI
Treatment for adult HIV infection : 2006 recommendations of the international AIDS society-USA panel
Scott M. Hammer,Michael S. Saag,Mauro Schechter,Julio S. G. Montaner,Robert T. Schooley,Donna M. Jacobsen,Melanie A. Thompson,Charles C. J. Carpenter,Margaret A. Fischl,Brian Gazzard,Jose M. Gatell,Martin S. Hirsch,David Katzenstein +12 more
TL;DR: The virologic target for patients with treatment failure is now a plasma HIV-1 RNA level below 50 copies/mL, making delivery of state-of-the-art care challenging.